Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr Gordon on Managing Toxicities Associated With Liso-Cel in MCL

November 19th 2024

Leo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

November 19th 2024

Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.

Bendamustine/Obinutuzumab Induction Generates Responses and MRD Negativity in Treatment-Naive MCL

November 18th 2024

Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma

November 5th 2024

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Dr Kamdar on the Safety Profile of Liso-Cel Across Patient Subgroups in MCL

October 31st 2024

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 10/20

October 26th 2024

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

Dr Gordon on the Clinical Implications of the TRANSCEND NHL 001 Trial of Liso-Cel in R/R MCL

October 24th 2024

Leo I. Gordon, MD, discusses the clinical implications of findings from the mantle cell lymphoma cohort of the TRANSCEND NHL 001 trial evaluating liso-cel.

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

October 22nd 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

Dr Gordon on Next Steps for Optimizing Liso-Cel Use in R/R MCL

October 17th 2024

Leo I. Gordon, MD, discusses future steps for optimizing the use of lisocabtagene maraleucel in the treatment of relapsed/refractory mantle cell lymphoma.

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma

October 14th 2024

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

FDA Grants Priority Review to Acalabrutinib in Treatment-Naive Mantle Cell Lymphoma

October 3rd 2024

The FDA granted priority review to acalabrutinib for previously untreated mantle cell lymphoma.

Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL

September 27th 2024

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

Novel BTK Inhibitor LP-168 Under Investigation in China for R/R Mantle Cell Lymphoma

September 20th 2024

The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.

Zanubrutinib/Rituximab Induction May Be Safe and Effective in Newly Diagnosed Mantle Cell Lymphoma

September 19th 2024

The chemotherapy-free induction regimen of zanubrutinib plus rituxumab produced response rates in patients with newly diagnosed mantle cell lymphoma.

First-Line Zanubrutinib/Obinutuzumab Shows Efficacy, Safety in Older MCL

September 19th 2024

The frontline combination of obinutuzumab and zanubrutinib demonstrated efficacy and safety in older patients with mantle cell lymphoma.

Dr Gordon on Shifts in the R/R MCL Treatment Paradigm

September 18th 2024

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

Dr Danilov on Ongoing MCL Clinical Trials

September 11th 2024

Alexey Danilov, MD, PhD, discusses ongoing investigations taking place to improve the treatment of patients with mantle cell lymphoma.

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL

September 6th 2024

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.